Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time. The FDA approved capivasertib, sold as Truqap by AstraZeneca, on June 12, ...

Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO (ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis ...

From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus ...

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer. The Food and Drug ...

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We ...

Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone ...

Abiraterone acetate is used along with prednisolone (corticosteroid) for treating a type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) previously called ...

A digital pathology multimodal AI test predicted a benefit from adding abiraterone to standard long-term androgen deprivation therapy (ADT) and radiotherapy in very high-risk, nonmetastatic prostate ...

I am extremely pleased that after a highly convoluted process and several knock-backs, the pioneering cancer drug abiraterone has finally been recommended by NICE for men with advanced prostate cancer ...